RELEASE DATE:  April 3, 2003

PA NUMBER:  PAR-03-093 (This PA has been reissued, see PAR-05-065)
                       (This Program Announcement (PAR) replaces PAR-00-033, which was published in 
the NIH Guide on December 22, 1999.)  

EXPIRATION DATE:  February 2, 2005 

National Cancer Institute (NCI)



o Purpose of the PAR
o Objectives of the Cancer Education Grant Program
o Mechanism of Support 
o Eligible Institutions
o Individuals Eligible to Become Principal Investigators
o Special Requirements
o Where to Send Inquiries
o Submitting an Application
o Peer Review Process
o Review Criteria   
o Award Criteria
o Required Federal Citations


The purpose of the Cancer Education Grant Program (CEGP) is to support the 
development and dissemination of innovative education approaches, methods and 
tools that ultimately will have an impact on reducing cancer incidence, 
mortality, morbidity, and improving the quality of life of cancer survivors. 


Background: The Cancer Education Grant Program, which employs the R25 grant 
mechanism, was reorganized in 1993 to provide institutions a wide range of 
opportunities to develop and sustain unique, innovative, primarily 
curriculum-driven programs that focus on various cancer education activities 
as opposed to the conduct of biomedical research.  The development of more 
refined, more effective education methods and tools for biomedical 
scientists, health care professionals, students and the lay community are 
essential components of the overall mission of the National Cancer Institute 
to reduce cancer incidence and mortality. Unlike typical research grants, 
which test research outcomes using experimental controls, R25 grants are 
experiments in new educational approaches that determine their success or 
failure through the application of carefully designed evaluation plans.

Objectives: The Cancer Education Grant Program of the National Cancer 
Institute is a flexible, primarily curriculum-driven program aimed at 
developing and sustaining innovative educational approaches that ultimately 
will have an impact on reducing cancer incidence, morbidity, mortality, and 
on improving the quality of life of cancer survivors. The CEGP invites 
investigator-initiated R25 grant applications that pursue a wide range of 
objectives from short courses, national forums, seminars, and/or hands-on 
workshops designed to educate scientists, health care professionals, students 
and the lay community; to the design, development and evaluation of new 
curricula of special significance to cancer in educational institutions; 
structured short-term didactic and research experiences designed to motivate 
high school, college and medical, dental and other health professional 
students to pursue careers in cancer research; to the development and 
evaluation  of new educational methods and tools directed at special 
audiences (e.g., minorities and underserved populations); to web-based and 
virtual approaches to cancer education.  The ranges of possibilities for this 
award are unlimited; as long as they focus on new approaches to cancer 
education, can be disseminated effectively, and potentially have wide 

Because of the wide spectrum of possible ways to use the Cancer Education 
Program, all applicants are urged to contact NCI program staff before 
preparing an application (see WHERE TO SEND INQUIRIES)


The NCI Cancer Education Grant Program uses the NIH R25 grant mechanism.  As 
an applicant, you will be solely responsible for planning, directing, and 
executing the proposed project.

New applicants may request up to five years of support in a single grant 
period in order to develop or maintain a specific education program.  The 
maximum support in direct costs per year is $300,000.  Applications exceeding 
this cap will be returned unless specific permission has been obtained in 
writing from the NCI program staff.  Facilities and administration (F & A) 
costs, which formerly were called indirect costs, will be reimbursed at 8 
percent of the modified direct costs.  It is important to note that 
subcontracts are also restricted to the same 8% reimbursement of modified 
direct costs.  For purposes of determining the cap, indirect costs included 
in a subcontract will not count against the direct cost cap.

Independently from the amount requested, this PAR does not use a modular 
budget.  A complete and detailed budget should be submitted.  This PAR is not 
subject to "Just-in-time" application procedures or to the Streamlined Non-
competing Application Process (SNAP).  The R25 remains under "Expanded 
Authorities" except that carryover of funds from one fiscal year to the next 
requires approval by the NCI. 

In general, allowable costs must be consistent with NIH policy and the 
recommendations of peer reviewers.  These costs include but are not limited 
to the following:  personnel costs, supplies, student compensation (when 
appropriate), student subsistence allowance (e.g., partial costs for meals 
and/or for lodging, when appropriate), other student costs (e.g., tuitions, 
travel expenses, when appropriate), consultant costs, equipment, travel, 
subcontractual costs (as long as subcontracts are not awarded with a higher 
indirect cost than 8%), and other expenses. It is recommended that potential 
applicants consult NCI staff if there are any questions regarding allowable 

Because the CEGP is primarily intended to support studies that can be 
completed within five years and sustained afterwards with other resources 
(e.g., institutional, community), all applications submitted as competing 
renewals must receive prior consultation and written approval from NCI 
program staff.  Programs with reasonable justification, such as short-term 
cancer research and educational experiences designed to motivate individuals 
to pursue cancer research careers (e.g., medical students) or educational 
programs for disadvantaged, underserved and minority populations that 
experience higher cancer incidence and mortality, are generally approved for 


o  Domestic (See below for exceptions) 
o  For Profit or non-profit organizations and professional societies
o  Public or private institutions, such as universities, colleges, hospitals, 
   and laboratories
o  Units of State and local governments
o  Eligible agencies of the Federal government
o  Faith-based or community-based organizations

Eligibility to apply for a grant is normally limited to domestic 
institutions.  Under special circumstances foreign institutions may request a 
formal waiver of this requirement after consulting with and receiving written 
approval from NCI. 


The Program Leader/Principal Investigator must be an expert 
educator/investigator in the proposed field and be able to provide both 
administrative and scientific leadership to the Program.  Racial/ethnic 
minority individuals, women, and persons with disabilities are encouraged to 
apply as principal investigators.


R25 grant applications submitted under this announcement may not be used to 
conduct traditional research or training.  

The NCI requires that R25 grant applications submitted in response to this 
announcement contain two special sections:  (1) an "Evaluation Plan" that 
clearly denotes how the proposed education program will be evaluated for 
success or failure based on its purpose and objectives. One of the evaluation 
criteria should focus on the degree of applicability the proposed program 
will have to other educational institutions, geographic areas and/or 
different populations; and (2) a "Dissemination Plan" that clearly indicates 
how the applicant will communicate and make available the results of the 
study (e.g., publications, presentations) to the potential user community 
(e.g., cancer centers, universities and other educational institutions, 
professional societies, communities etc.).  Applications submitted without 
these two sections will not receive further consideration.

When the application is designed for completion within a five year period or 
less using Federal resources AND is expected to continue without additional 
Federal support, the applicant institution must include a plan, with 
appropriate commitment of resources, to continue the effort after the period 
of grant support ends.  Examples of these kinds of studies might be 
curriculum development within the institution in areas of critical importance 
to cancer education (e.g., nutrition, pain management) or efforts directed to 
the community (e.g., outreach programs to the lay public, educational 
programs for community health care professionals).  

A final progress report, invention statement, and Financial Status Report are 
required upon termination of an award.

Evaluation from NCI:  In carrying out its stewardship of human resource 
related programs, the NCI may request information essential to an assessment 
of the effectiveness of this program.  Accordingly, recipients are hereby 
notified, that they may be contacted after the completion of this award for 
periodic updates on various aspects of the educational program including, but 
not limited to, achievement obtained through the program, trainee 
accomplishments, publications, dissemination, honors and awards, professional 
activities, and other information helpful in evaluating the impact of the 


We encourage your inquiries concerning this PAR and welcome the opportunity 
to answer questions from potential applicants.  Inquiries may fall into three 
areas:  scientific/research, peer review, and financial or grants management 

o Direct your questions about scientific/research issues to:

Dr. Maria Agelli
National Cancer Institute
Cancer Training Branch
6116 Executive Boulevard, Suite 700
Bethesda, MD  20892
Telephone: (301) 496-8580

o Direct your questions about peer review issues to:

Referral Officer 
National Cancer Institute
Division of Extramural Activities
6116 Executive Boulevard, Room 8041, MSC 8329
Bethesda, MD 20892-8329
Telephone: (301) 496-3428
FAX: (301) 402-0275 

o Direct your questions about financial or grants management matters to:

Ms. Catherine Blount
National Cancer Institute
Grants Administration Branch
6120 Executive Blvd.
Room EPS 243
Bethesda, MD 20892
Phone: (301) 496-3179
Fax: (301) 496-8601


Applications should be prepared using the PHS 398 research grant application 
instructions and forms (rev. 5/2001).  The CEGP allows for a wide range of 
approaches and topics but applicants are expected to generally follow the 
instructions and Table of Contents provided in the PHS 398-application kit 
with respect to the organization of the application.  The PHS 398 is 
available at in an 
interactive format.  For further assistance contact GrantsInfo, Telephone 
(301) 710-0267, Email:

The instructions in the Form PHS 398 do not fully apply to the special needs 
of this grant application.  Therefore, please follow the modified 
instructions below in preparing an application for an NCI Cancer Education 
Grant (R25) Program.  These instructions have been adapted to accommodate the 
Form PHS 398 and the special needs of the CEGP:

1.  Face Page:  Use Form Page 1 of the Form PHS 398.  On Line 1, include the 
title that best represents the nature of the training program.  On Line 2, 
provide the number of this Program Announcement beginning with PAR-03-093, 
and the title "Cancer Education Grant Program (R25)".

2.  Description/ Performance site(s)/ Key personnel (Form Page 2 of Form PHS 
398): Under Performance Sites include "Consortium/ Contractual Arrangements" 
with a description of plans for collaborating with other institutions for the 
purpose of exchange and sharing of resources including faculty, equipment and 
facilities.  If multiple sites are to be used, the applicant institution must 
be one of those sites and a strong justification must be provided for 
inclusion of the other sites in the proposed education program.

3.  Resources:  Use the Resource Format page and describe the educational 
environment.  Include in this description the facilities, laboratories, 
participating departments, and any other resources to be used in the conduct 
of the proposed program.  Use continuation pages as necessary.

4.  Research Plan
    o Retitle Part C. "Preliminary Activities" and include if applicable.  
This section should contain information on the steps that have led to the 
proposed program.

    o Retitle Part D of this section "Cancer Education Program Plan". The 
information provided in this section should be organized as follows: 

a. Program Direction.  Describe the qualifications and role of the PI to 
provide scientific and administrative leadership and coordination of the 
Program and the plans for management of the program.

b. Program Faculty/ Staff.  Describe the experience and responsibilities of 
the faculty and staff. 

c. Proposed Cancer Education Program. Briefly describe the background, 
purpose and objectives of the Program.  Provide programmatic detail on 
special activities proposed (e.g., courses, curricula, workshops, etc.) as 
well as evidence of institutional and community commitment and support of the 
proposed program.  Where appropriate, provide information on the proposed 
participants, and the plans for recruiting and retaining participants, 
including individuals from underrepresented racial/ethnic groups, women and 
persons with disabilities.

d. Cancer Education Evaluation Plan.  Provide a plan for evaluating the 
success of the program in achieving its goals and objectives.  Applications 
that do not have an adequate evaluation plan will be considered non-
responsive to this program announcement.  

e. Dissemination Plan.  Provide a plan for disseminating the knowledge 
acquired from the education program.  The plan should include a description 
of the venues that will be used and the populations, institutions, 
organizations, etc., that will be targeted for receiving information about 
the program.  Applications that do not have an adequate dissemination plan 
will be considered non-responsive to this program announcement.  

f. Statement of Institutional Commitment.  Where appropriate, evidence of 
institutional commitment and plans to continue funding the educational 
program after the period of grant support ends.  

5. Human Subjects.  The revised policy for IRB review of human subjects 
protocols in grant applications can be found at the following URL:

APPLICATION RECEIPT DATES: Applications submitted in response to this program 
announcement will be accepted at the standard application deadlines, which 
are available at  Application 
deadlines are also indicated in the PHS 398 application kit.

SENDING AN APPLICATION TO THE NIH: Submit a signed, typewritten original of 
the application, including the checklist, and three signed photocopies in one 
package to:

Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD  20892-7710
Bethesda, MD  20817 (for express/courier service)

To expedite the review process, which will be conducted by the NCI, two 
additional copies must be sent to:

Referral Officer
Division of Extramural Activities
National Cancer Institute
6116 Executive Boulevard, Room 8041, MSC 8329
Bethesda, MD  20892-8329
Rockville, MD  20852 (for express/courier service)

WILL NO LONGER BE ACCEPTED.  This policy does not apply to courier deliveries 
(i.e. FEDEX, UPS, DHL, etc.) (
NOT-CA-02-002.html)  This change in practice is effective immediately.  
This policy is similar to and consistent with the policy for applications 
addressed to Centers for Scientific Review as published in the NIH Guide 

APPLICATION PROCESSING: Applications must be received by the date(s) listed 
on the first page of this PAR.  The CSR will not accept any application in 
response to this PAR that is essentially the same as one currently pending 
initial review unless the applicant withdraws the pending application.  The 
CSR will not accept any application that is essentially the same as one 
already reviewed.  This does not preclude the submission of a substantial 
revision of an application already reviewed, but such application must 
include an Introduction addressing the previous critique

Although there is no immediate acknowledgement of the receipt of an 
application, applicants are generally notified of the review and funding 
assignment within 8 weeks.


Upon receipt, applications will be reviewed for completeness by the CSR and 
for adherence to the guidelines of this PAR by the NCI program staff.  
Applications not adhering to the guidelines of this PAR, and those 
applications that are incomplete as determined by CSR or by NCI program 
staff, will not receive further consideration.  Applications that are 
complete and adhere to the guidelines of this PAR will be evaluated for 
scientific and technical merit by an appropriate peer review group convened 
by the Division of Extramural Activities of the NCI in accordance with the 
review criteria stated below.  

As part of the initial merit review, all applications will:

o  Receive a written critique
o  Undergo a process in which only those applications deemed to have the 
highest scientific merit, generally the top half of the applications under 
review, will be discussed and assigned a priority score
o  Those that receive a priority score will undergo a second level review by 
the National Cancer Advisory Board.


The goals of NIH-supported research are to advance our understanding of 
biological systems, improve the control of disease, and enhance health.  In 
the written comments, reviewers will be asked to discuss the following 
aspects of your application in order to judge the likelihood that the 
proposed research will have a substantial impact on the pursuit of these 

1.  Novelty and significance of the education program to cancer research 
and/or to the reduction of cancer incidence, morbidity, and mortality and to 
the improvement of quality of life of cancer survivors.

2.  Quality of the program leader (principal investigator) in terms of past 
track record of achievement and experience to provide direction, 
coordination, and administration of the Program.

3.  Quality of the key personnel and/or faculty who will participate in the 

4.  The overall quality and adequacy of the design of the Program to achieve 
its short-term and long-term objectives.

5.  Where appropriate, adequacy of plans for recruitment and retention of 
program participants, including participants from underrepresented 
racial/ethnic groups, women and persons with disabilities.

6.  Degree of applicability and portability of the proposed program to other 
institutions, geographic areas, and populations.

7.  Adequacy of the required "Evaluation Plan" to assess the effectiveness of 
the Program in achieving its objectives.

8.  Adequacy of the "Dissemination Plan" to communicate and make available 
the results of the study through publications in professional journals, 
publications/presentations at national and international meetings, and 
internet websites; and to reach the potential user community effectively 
(e.g., cancer centers, universities and other educational institutions, 
professional societies, hospitals, other educators).  

9.  When the program is expected to continue without additional Federal 
Resources, sufficiency of the applicant institution's plan and commitment of 
resources to continue the Program after the period of Federal grant support 

10. The following review criteria apply only to proposed education programs 
that involve short-term experiences in a research environment and which are 

a.  Quality of the proposed short-term education program, taking into account 
the quality (and track records, if a renewal application) of the program 
design, and of the educational environment; the commitment of the 
participating faculty; the availability of research support, inclusion of 
information related to new, rapidly developing topics/fields in biomedical 

b.  Access to candidates for short-term experiences and the ability to 
recruit high quality individuals from the applicant institution or other 
schools.  Evaluate the track record for a renewal application.

c.  Characteristics of the educational program that might be expected to 
persuade short-term participants to consider cancer research careers.  
Evaluate the track record for a renewal application.

d.  Success in attracting students back for repeated short-term appointments.

e.  Success in recruiting under-represented minorities.

f.  Plan to follow former participants and to assess the effect of such a 
program on their research careers. Evaluate the track record for a renewal 

11. For all other renewal applications, the track record of productivity.

ADDITIONAL REVIEW CRITERIA: In addition to the above criteria, the initial 
review group will also evaluate:

subjects and protections from research risk relating to their participation 
in the proposed research will be assessed. (See criteria included in the 
section on Federal Citations, below).

plans to include subjects from both genders, all racial and ethnic groups 
(and subgroups), and children as appropriate for the scientific goals of the 
research will be assessed.  Plans for the recruitment and retention of 
subjects will also be evaluated. (See Inclusion Criteria in the sections on 
Federal Citations, below).

be used in the project, the five items described under Section f of the PHS 
398 research grant application instructions (rev. 5/2001) will be assessed.  


BUDGET:  Appropriateness of the budget and duration of the support needed to 
achieve the stated goals and objectives.


Applications submitted in response to a PAR will compete for available funds 
with all other recommended applications.  The following will be considered in 
making funding decisions:  

o Educational merit of the proposed project as determined by peer review
o Availability of funds 
o Relevance to program priorities


HUMAN SUBJECTS PROTECTION: Federal regulations (45CFR46) require that 
applications and proposals involving human subjects must be evaluated with 
reference to the risks to the subjects, the adequacy of protection against 
these risks, the potential benefits of the research to the subjects and 
others, and the importance of the knowledge gained or to be gained.

the NIH that women and members of minority groups and their sub-populations 
must be included in all NIH-supported clinical research projects unless a 
clear and compelling justification is provided indicating that inclusion is 
inappropriate with respect to the health of the subjects or the purpose of 
the research. This policy results from the NIH Revitalization Act of 1993 
(Section 492B of Public Law 103-43).

All investigators proposing clinical research should read the AMENDMENT "NIH 
Guidelines for Inclusion of Women and Minorities as Subjects in Clinical 
Research - Amended, October, 2001," published in the NIH Guide for Grants and 
Contracts on October 9, 2001 (
NOT-OD-02-001.html); a complete copy of the updated Guidelines are 
available at
amended_10_2001.htm.The amended policy incorporates: the use of an NIH 
definition of clinical research; updated racial and ethnic categories in 
compliance with the new OMB standards; clarification of language governing 
NIH-defined Phase III clinical trials consistent with the new PHS Form 398; 
and updated roles and responsibilities of NIH staff and the extramural 
community.  The policy continues to require for all NIH-defined Phase III 
clinical trials that: a) all applications or proposals and/or protocols must 
provide a description of plans to conduct analyses, as appropriate, to address 
differences by sex/gender and/or racial/ethnic groups, including subgroups if 
applicable; and b) investigators must report annual accrual and progress in 
conducting analyses, as appropriate, by sex/gender and/or racial/ethnic group 

The NIH maintains a policy that children (i.e., individuals under the age of 
21) must be included in all human subjects research, conducted or supported 
by the NIH, unless there are scientific and ethical reasons not to include 
them. This policy applies to all initial (Type 1) applications submitted for 
receipt dates after October 1, 1998.

All investigators proposing research involving human subjects should read the 
"NIH Policy and Guidelines" on the inclusion of children as participants in 
research involving human subjects that is available at 

policy requires education on the protection of human subject participants for 
all investigators submitting NIH proposals for research involving human 
subjects.  You will find this policy announcement in the NIH Guide for Grants 
and Contracts Announcement, dated June 5, 2000, at  A 
continuing education program in the protection of human participants in 
research in now available online at:     

HUMAN EMBRYONIC STEM CELLS (hESC): Criteria for federal funding of research 
on hESCs can be found at and at  Guidance 
for investigators and institutional review boards regarding research 
involving human embryonic stem cells, germ cells, and stem cell-derived test 
articles can be found at
NOT-OD-02-044.html. Only research using hESC lines that are registered in 
the NIH Human Embryonic Stem Cell Registry will be eligible for Federal funding
(see   It is the 
responsibility of the applicant to provide the official NIH identifier(s)for 
the hESC line(s) to be used in the proposed research.  Applications that do 
not provide this information will be returned without review.

Office of Management and Budget (OMB) Circular A-110 has been revised to 
provide public access to research data through the Freedom of Information Act 
(FOIA) under some circumstances.  Data that are (1) first produced in a 
project that is supported in whole or in part with Federal funds and (2) 
cited publicly and officially by a Federal agency in support of an action 
that has the force and effect of law (i.e., a regulation) may be accessed 
through FOIA.  It is important for applicants to understand the basic scope 
of this amendment.  NIH has provided guidance at

Applicants may wish to place data collected under this PAR in a public 
archive, which can provide protections for the data and manage the 
distribution for an indefinite period of time.  If so, the application should 
include a description of the archiving plan in the study design and include 
information about this in the budget justification section of the 
application. In addition, applicants should think about how to structure 
informed consent statements and other human subjects procedures given the 
potential for wider use of data collected under this award.

Department of Health and Human Services (DHHS) issued final modification to 
the "Standards for Privacy of Individually Identifiable Health Information", 
the "Privacy Rule," on August 14, 2002.  The Privacy Rule is a federal 
regulation under the Health Insurance Portability and Accountability Act 
(HIPAA) of 1996 that governs the protection of individually identifiable 
health information, and is administered and enforced by the DHHS Office for 
Civil Rights (OCR). Those who must comply with the Privacy Rule (classified 
under the Rule as "covered entities") must do so by April 14, 2003  (with the 
exception of small health plans which have an extra year to comply).  

Decisions about applicability and implementation of the Privacy Rule reside 
with the researcher and his/her institution. The OCR website 
( provides information on the Privacy Rule, including 
a complete Regulation Text and a set of decision tools on "Am I a covered 
entity?"  Information on the impact of the HIPAA Privacy Rule on NIH 
processes involving the review, funding, and progress monitoring of grants, 
cooperative agreements, and research contracts can be found at

URLs IN NIH GRANT APPLICATIONS OR APPENDICES: All applications and proposals 
for NIH funding must be self-contained within specified page limitations. 
Unless otherwise specified in an NIH solicitation, Internet addresses (URLs) 
should not be used to provide information necessary to the review because 
reviewers are under no obligation to view the Internet sites.   Furthermore, 
we caution reviewers that their anonymity may be compromised when they 
directly access an Internet site.

HEALTHY PEOPLE 2010:  The Public Health Service (PHS) is committed to 
achieving the health promotion and disease prevention objectives of "Healthy 
People 2010," a PHS-led national activity for setting priority areas. This 
PAR, Cancer Education Grant Program, is related to the priority area of 
cancer education and community–based programs. Potential applicants may 
obtain a copy of "Healthy People 2010" at

AUTHORITY AND REGULATIONS:  This program is described in the Catalog of 
Federal Domestic Assistance No. 93.398 at, and is not 
subject to the intergovernmental review requirements of Executive Order 12372 
or Health Systems Agency review.  Awards are made under authorization of 
Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 
and 284) and administered under NIH grants policies described at and under Federal Regulations 
42 CFR 52 and 45 CFR Parts 74 and 92.

The PHS strongly encourages all grant recipients to provide a smoke-free 
workplace and discourage the use of all tobacco products.  In addition, 
Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in 
certain facilities (or in some cases, any portion of a facility) in which 
regular or routine education, library, day care, health care, or early 
childhood development services are provided to children.  This is consistent 
with the PHS mission to protect and advance the physical and mental health of 
the American people.

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.